You are here

Pacific Biosciences of California, Inc. Announces Third Quarter 2018 Financial Results

MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2018.

Total revenue for the third quarter of 2018 was $18.2 million, compared to $23.5 million for the third quarter of 2017, primarily driven by lower instrument shipments and consumables sales.  Lower consumable sales were due to lower demand of PacBio RS II consumables and variation in customer ordering patterns.  Despite lower consumable sales, usage of installed Sequel instruments increased significantly during  the third quarter of 2018 compared with the third quarter of 2017.

Gross profit for the third quarter of 2018 was $3.2 million, resulting in a gross margin of 17.6%. Gross profit for the third quarter of 2017 was $8.2 million, resulting in a gross margin of 34.9%. Gross profit for the three-month period ended September 30, 2018 was negatively impacted by $2.4 million of product transition costs. In addition, lower manufacturing output during the three-month period ended September 30, 2018 also negatively impacted gross profit as a larger portion of manufacturing fixed costs was reflected in cost of sales for the period.

Operating expenses for the third quarter of 2018 totaled $27.9 million, compared to $29.8 million for the third quarter of 2017. Operating expenses for the third quarter of 2018 and 2017 included non-cash stock-based compensation of $4.5 million and $4.4 million, respectively.

Net loss for the third quarter of 2018 was $25.0 million, compared to $22.0 million for the third quarter of 2017.

Cash, cash equivalents and investments, excluding restricted cash, at September 30, 2018 totaled $115.7 million, compared to $62.9 million at December 31, 2017. The Company received $64.9 million in net proceeds excluding offering expenses from a public offering of common stock in September 2018. Excluding the above net proceeds of $64.9 million collected from our public offering, our cash burn in the third quarter of 2018 was approximately $12.6 million, compared with approximately $15.7 million in the second quarter of 2018.

Commenting on the third quarter results, Mike Hunkapiller, Chairman and CEO of PacBio noted, “Some of our customers held back in purchasing products during the third quarter in anticipation of the new products we recently launched or have announced we are planning to launch early next year.  However, we have been very pleased with the enthusiastic response from our customers on the launch of our new 3.0 chemistry and 6.0 software in October.  We are also looking forward to the launch of our new 8M SMRT Cell and platform, with early access scheduled to begin during the first quarter of 2019.  We are also excited to announce the proposed merger with Illumina, which we believe will enable the combined company to provide SMRT Sequencing to a broader range of customers and at a much faster rate than we could have accomplished on our own.”

Conference Call Information

The Company will not be hosting a separate conference call to discuss its third quarter ending September 30, 2018 results.  A joint conference call with Illumina will be hosted at 5:00 p.m. Eastern Time.  Interested parties may listen to the call by 1.800.708.4540 toll free in the US, or 1.847.619.6397, using Conference ID # 47821173.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.  More information is available at

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development and commercialization of products, future uses, quality or performance of, or benefits of using, products or technologies, the proposed merger with Illumina and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Trevin Rard

Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(amounts in thousands, except per share amounts)

 Three Months Ended September 30,  Nine Months Ended September 30,
 2018 2017 2018 2017
Product revenue$ 15,150  $ 20,343  $ 49,917  $ 58,185 
Service and other revenue  3,010    3,202    9,183    10,348 
Total revenue  18,160    23,545    59,100    68,533 
Cost of Revenue:           
Cost of product revenue  12,250    11,547    31,127    31,064 
Cost of service and other revenue  2,718    3,771    8,623    12,304 
Total cost of revenue  14,968    15,318    39,750    43,368 
Gross profit  3,192    8,227    19,350    25,165 
Operating Expense:           
Research and development  14,356    15,844    46,331    49,698 
Sales, general and administrative  13,506    13,952    43,383    44,722 
Total operating expense  27,862    29,796    89,714    94,420 
Operating loss  (24,670)   (21,569)   (70,364)   (69,255)
Interest expense  (616)   (633)   (1,795)   (2,297)
Other income, net  242    181    396    125 
Net loss$ (25,044) $ (22,021) $ (71,763) $ (71,427)
Basic and diluted net loss per share$ (0.19) $ (0.19) $ (0.55) $ (0.70)
Shares used in computing basic and diluted net loss per share  135,130    115,771    130,302    102,117 

Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(amounts in thousands)

 September 30, December 31,
 2018 2017
Cash and investments$ 115,747 $ 62,872
Accounts receivable  6,404   13,433
Inventory  19,694   23,065
Prepaid and other current assets  2,028   2,249
Property and equipment  34,490   37,920
Long-term restricted cash  4,500   4,500
Other long-term Assets  43   45
Total Assets$ 182,906 $ 144,084
Liabilities and Stockholders' Equity     
Accounts payable$ 5,966 $ 9,093
Accrued expenses  9,298   12,618
Deferred service revenue  6,756   7,394
Deferred rent  13,949   14,453
Other liabilities  645   605
Financing derivative  28   183
Notes payable  14,384   13,635
Stockholders' equity  131,880   86,103
Total Liabilities and Stockholders' Equity$ 182,906 $ 144,084
Thursday, November 1, 2018 - 16:15